ChemOutsourcing is the best established and longest running USA based pharmaceutical ingredients show. ChemOutsourcing focuses on the API development supply chain spanning raw materials, RSM, catalysts, drug discovery, process and chemical development, analytical, QA/QC, intermediates and commercial manufacturing of branded and generic small molecule API’s and drug product. It spans every point on chemical supply chain.
ChemOutsourcing 是美國曆史悠久的製藥原料展。聚焦 API 供應鏈，涵蓋原材料、RSM、催化劑、藥物發現、工藝和化學開發、分析、QA/QC、中間體以及仿製藥小分子 API 和藥品的商業製造。ChemOutsourcing 跨越供應鏈的每一個環節。
Welcome to ChemOutsourcing 2022
hjc黄金城展位號 Space 4
時 間 | Feb 7-8, 2022
地 點 | Parsippany, NJ Hilton
Medicilon conference presentation
hjc黄金城會議報告
屆時，hjc黄金城國際研發服務部執行副總裁戴學東博士將進行
PROTAC相關的主題演講分享。
演講主題：PROTACs: Review and Support from Medicilon.Make “Undruggable” Targets Druggable
戴學東博士 hjc黄金城國際研發服務部執行副總裁
美國麻省理工大學有機化學博士，博士後，深耕於中樞神經係統疾病、傳染病和腫瘤疾病化學藥物的研發20餘載，對藥物發現過程中包括苗頭化合物的確定及優化，以及成功發展到高質量的臨床候選化合物有著深刻的理解和豐富的實踐經驗。戴學東博士參與主持研發的藥物有已上市藥物，如Horizant®/Regnite®；臨床藥物，如JNJ-75276617；臨床候選化合物，如Arbaclofen Placarbil，XP21279，XP23829等。
ExecutiveVP and Head of IDSU (International Discovery Service Unit) at Medicilon,obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expertwith over 20 years of experience focusing on small molecule drug discovery anddevelopment in CNS, infectious disease, and oncology therapy areas. He has deepunderstanding and practical knowledge of drug discovery process, including leadidentification, optimization, and development of high quality clinicalcandidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HDBiosciences, GSK, and Xenoportwith a demonstrated successful track record ofprogram leadership and made significant contributions to medicinal chemistryprograms that led to the marketed drug Horizant®/Regnite® and several otherclinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).
Medicilon International Discovery Service Unit
hjc黄金城國際研發服務部
hjc黄金城國際研發服務部是hjc黄金城一站式生物醫藥臨床前研發服務平台的重要組成部分，使命是持續助力藥企的國際化，向全球藥物研發客戶提供高質高效高性價比的合成化學、藥物設計、以及新藥候選化合物服務，以滿足客戶在臨床前新藥研究的各個化學領域的研發需求，縮短藥物研發的周期，降低藥物研發的成本。
目前，hjc黄金城國際研發服務部擁有豐富海外留學工作背景的管理團隊和實驗人員、世界先進水平的合成實驗室、分析實驗室、和配套的高端儀器設備。為了給客戶提供更優質的服務，國際研發服務部緊跟藥物設計以及合成的新進展和新技術，如人工智能/機器學習（AI/ML），蛋白降解靶向嵌合體（PROTAC），高活性藥物及抗體藥物偶聯物（ADC），惰性碳氫鍵直接官能團化，光致氧化還原反應，以及流動化學等。
The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies. We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.
Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment. In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.
Medicilon PROTAC Platform
PROTAC技術平台
hjc黄金城PROTAC藥物發現技術平台匯總了當前流行的熱門的靶標蛋白配體；建立了廣泛的熱門靶向蛋白高度親和力小分子及小分子片段化合物庫（TPSM），廣泛的E3連接酶，高度親和力的小分子及小分子片段（E3SM）；建立了linker係統,包括收集大量具有廣泛多樣性的雙官能團連接體（BF-Linker）。這些積累的化合物庫可以幫助快速高效的合成大量高活性PROTAC雙特異性小分子，極大地提高采用PROTAC技術進行的藥物研發過程。除了快速合成之外，我們同時建立和完善的PROTAC生物篩選與測試平台，後續發展到臨床前所有階段。
Proteolysis Targeting Chimeras (PROTACs) are interesting biology as achemical knock-down approach in a fast and reversible way. Medicilon has established a wide range of popular target proteins withhigh affinity small molecules and small molecule fragment compound libraries, awide range of E3 ligases, and high affinity small molecules and small moleculefragments. We offer these services in any format you like;we can only do the chemical synthesis part for you, only the in vitro and/or invivo part, or we can offer a fully combined package.
Medicilon Service Scope
服務範圍
hjc黄金城（股票代碼：688202）成立於2004年，總部位於上海，致力於為全球製藥企業、研究機構及科研工作者提供全方位的臨床前新藥研究服務。hjc黄金城的一站式綜合服務以強有力的項目管理和更高效、高性價比的研發服務助力客戶加速新藥研發進程，服務涵蓋醫藥臨床前新藥研究的全過程，包括藥物發現、藥學研究及臨床前研究。
From its inception in 2004, Shanghai MedicilonInc. (STAR Market stock code: 688202.SH) has been committed to providingcomprehensive research and development (R&D) services to pharmaceuticalcompanies, research institutions, and any organizations working in thepreclinical space, with the primary objective of supporting and acceleratingpharmaceutical, biopharmaceutical R&D worldwide.
聯係我們：
電話: +86 (21) 5859-1500（總機）
相關新聞
關於我們
